Confirmatory Clinical Trial for Verifying the Efficacy and Safety of 'ALZGUARD' as a Digital Dementia Diagnostic Aid-Tool for the Diagnosis of the Major Neurocognitive Disorders

HAII corp.ltd122 enrolled

Overview

The goal of this clinical trial is to evalute the efficacy of ALZGUARD, a smartphone-based digital therapeutic(DTx), in comparison to diagnosis by medical doctors, as weel as to assess the safety of the application.

The study will be conducted across multiple sites, enrolling participants aged 55 to 85 years olds. The primary objective of the study is to compare the diagnositic accuracy of ALZGAURD against traditional diagnostic evaluactions conducted by medical professionals. The primary endpoint for efficacy will be the Area Under the Curve(AUC), which will measure the diagnostic performance of the application. This statistical metric will help determine how well ALZGUARD can identify dementia compared to standard diagnostic methods.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

122

Conditions

Dementia Major Neurocognitive Disorder

Interventions

ALZGUARDDEVICE

A digital therapeutic(DTx) application that uses artifical intelligence to analyze cognitive function and provide a diagnosis of dementia.

Eligibility

Sex: ALLMin age: 55 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants must be between 55 and 85 years old (both men and women). * Participants must be able to understand and voluntarily agree to the purpose, content, and procedures of the clinical trial. Exclusion Criteria: * Participants with no literacy or illiteracy. * Participants with an intellectual disability. * Participants with presenting active psychiatric symptoms. * Participants who have difficulty ALZGUARD application * Participants who are unable to use a smartphone, unless they can use it with assistant. * Participants with a history of suicidal ideation or suicidal complusion in the last 6 months. * Other conditions as deemed inappropriate for study participant by the Principal Investigator(PI).

Locations (3)

Kangwon National University Hospital

Chuncheon, Gangwon-do, South Korea

RECRUITING

Ewha Womans University Mokdong Medical Center

Seoul, South Korea

RECRUITING

Yongin Severance Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Area Under the Curve (AUC)

The primary outcome will be the Area Under the Curve (AUC), which will assess the diagnostic accuracy of ALZGUARD by comparing its results with the clinical diagnosis made by neurologists. AUC will be calculated to determine the performance of ALZGUARD in detecting dementia.

Time frame: up to 8 months

Secondary Outcomes

Sensitivity

The one of the secondary outcome will measure the sensitivity of ALZGUARD in detecting dementia. Sensitivity refers to the proportion of true positive cases accurately identified by ALZGUARD, compared to clinical diagnosis made by neurologists. This measure will assess the ability of ALZGUARD to correctly identiry patients who have dementia.

Time frame: up to 8 months

Specificity

Specificity refers to the proportion of true negative cases accurately identified by ALZGUARD, compared to the clinical diagnosis made by neurologists. This outcome will assess the ability of ALZGUARD to correctly identify patient who do not have dementia.

Time frame: up to 8 months

Central Contacts

Rachel Lee

CONTACT

+82 10-7390-5023 rachel.lee@haii.io

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.